Vladimir Tolmachev

List of Publications by Year
in descending order

308	11,350	30070 54	49909 87
papers	citations	h-index	g-index

313	313	313	6253
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Letters, 2010, 584, 2670-2680.	2.8	521
2	Tumor Imaging Using a Picomolar Affinity HER2 Binding Affibody Molecule. Cancer Research, 2006, 66, 4339-4348.	0.9	462
3	Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic ¹¹¹In- or ⁶⁸Ga-Labeled Affibody Molecules. Journal of Nuclear Medicine, 2010, 51, 892-897.	5.0	271
4	First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the ¹¹¹In-ABY-025 Affibody Molecule. Journal of Nuclear Medicine, 2014, 55, 730-735.	5.0	211
5	Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [⁶⁸Ga]ABY-025 Affibody PET/CT. Theranostics, 2016, 6, 262-271.	10.0	204
6	Radionuclide Therapy of HER2-Positive Microxenografts Using a 177Lu-Labeled HER2-Specific Affibody Molecule. Cancer Research, 2007, 67, 2773-2782.	0.9	203
7	Synthetic Affibody Molecules: A Novel Class of Affinity Ligands for Molecular Imaging of HER2-Expressing Malignant Tumors. Cancer Research, 2007, 67, 2178-2186.	0.9	176
8	Selection and characterization of HER2/neu-binding affibody ligands. Protein Engineering, Design and Selection, 2004, 17, 455-462.	2.1	168
9	Extending Half-life by Indirect Targeting of the Neonatal Fc Receptor (FcRn) Using a Minimal Albumin Binding Domain. Journal of Biological Chemistry, 2011, 286, 5234-5241.	3.4	147
10	Pretargeted Imaging and Therapy. Journal of Nuclear Medicine, 2017, 58, 1553-1559.	5.0	143
11	Directed Evolution to Low Nanomolar Affinity of a Tumor-Targeting Epidermal Growth Factor Receptor-Binding Affibody Molecule. Journal of Molecular Biology, 2008, 376, 1388-1402.	4.2	138
12	Design of an Optimized Scaffold for Affibody Molecules. Journal of Molecular Biology, 2010, 398, 232-247.	4.2	137
13	On the Selection of a Tracer for PET Imaging of HER2-Expressing Tumors: Direct Comparison of a ¹²⁴I-Labeled Affibody Molecule and Trastuzumab in a Murine Xenograft Model. Journal of Nuclear Medicine, 2009, 50, 417-425.	5.0	131
14	Affibody molecules: potential forin vivoimaging of molecular targets for cancer therapy. Expert Opinion on Biological Therapy, 2007, 7, 555-568.	3.1	117
15	VEGFR2 pY949 signalling regulates adherens junction integrity and metastatic spread. Nature Communications, 2016, 7, 11017.	12.8	111
16	Imaging of HER-2 Overexpression in Tumors for Guiding Therapy. Current Pharmaceutical Design, 2008, 14, 2999-3019.	1.9	108
17	Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-ZEGFR:2377 Affibody molecule: aspect of the injected tracer amount. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 613-622.	6.4	103
18	Same-Day Imaging Using Small Proteins: Clinical Experience and Translational Prospects in Oncology. Journal of Nuclear Medicine, 2018, 59, 885-891.	5.0	101

#	Article	IF	Citations
19	^{99m}Tc-maEEE-Z_{HER2:342}, an Affibody Molecule-Based Tracer for the Detection of HER2 Expression in Malignant Tumors. Bioconjugate Chemistry, 2007, 18, 1956-1964.	3.6	98
20	Affibody Molecules for Epidermal Growth Factor Receptor Targeting In Vivo: Aspects of Dimerization and Labeling Chemistry. Journal of Nuclear Medicine, 2009, 50, 274-283.	5.0	98
21	Targeting of HER2-Expressing Tumors with a Site-Specifically ^{99m}Tc-Labeled Recombinant Affibody Molecule, Z_{HER2:2395}, with C-Terminally Engineered Cysteine. Journal of Nuclear Medicine, 2009, 50, 781-789.	5.0	97
22	Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. Lancet Oncology, The, 2010, 11, 992-1000.	10.7	91
23	Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors. Journal of Nuclear Medicine, 2005, 46, 1881-8.	5.0	90
24	Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule ⁶⁸Ga-ABY-025 in Breast Cancer Patients. Journal of Nuclear Medicine, 2016, 57, 867-871.	5.0	88
25	In Vitro Characterization of a Bivalent Anti-HER-2 Affibody with Potential for Radionuclide-Based Diagnostics. Cancer Biotherapy and Radiopharmaceuticals, 2005, 20, 239-248.	1.0	87
26	Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 722-733.	6.4	84
27	Evaluation of Maleimide Derivative of DOTA for Site-Specific Labeling of Recombinant Affibody Molecules. Bioconjugate Chemistry, 2008, 19, 235-243.	3.6	83
28	Targeting of HER2-Expressing Tumors Using ¹¹¹In-ABY-025, a Second-Generation Affibody Molecule with a Fundamentally Reengineered Scaffold. Journal of Nuclear Medicine, 2010, 51, 1131-1138.	5.0	81
29	Molecular Design and Optimization of ^{99m}Tc-Labeled Recombinant Affibody Molecules Improves Their Biodistribution and Imaging Properties. Journal of Nuclear Medicine, 2011, 52, 461-469.	5.0	80
30	99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 1843-1853.	6.4	79
31	Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer. Cancer Immunology Research, 2014, 2, 80-90.	3.4	78
32	Production of 76Br by a low-energy cyclotron. Applied Radiation and Isotopes, 1998, 49, 1537-1540.	1.5	75
33	A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1356-1367.	6.4	75
34	Site-Specific Radiometal Labeling and Improved Biodistribution Using ABY-027, A Novel HER2-Targeting Affibody Moleculeâ€“Albumin-Binding Domain Fusion Protein. Journal of Nuclear Medicine, 2013, 54, 961-968.	5.0	75
35	Radiolabelled proteins for positron emission tomography: Pros and cons of labelling methods. Biochimica Et Biophysica Acta - General Subjects, 2010, 1800, 487-510.	2.4	74
36	HEHEHE-Tagged Affibody Molecule May Be Purified by IMAC, Is Conveniently Labeled with [^{99m}Tc(CO)₃]⁺, and Shows Improved Biodistribution with Reduced Hepatic Radioactivity Accumulation. Bioconjugate Chemistry, 2010, 21, 2013-2022.	3.6	72

#	Article	IF	Citations
37	Tumor Targeting Using Affibody Molecules: Interplay of Affinity, Target Expression Level, and Binding Site Composition. Journal of Nuclear Medicine, 2012, 53, 953-960.	5.0	72
38	Engineering of Affibody Molecules for Therapy and Diagnostics. Methods in Molecular Biology, 2012, 899, 103-126.	0.9	72
39	111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. Journal of Nuclear Medicine, 2006, 47, 846-53.	5.0	72
40	Pharmacokinetics and red cell utilization of iron(III) hydroxideâ€“sucrose complex in anaemic patients: a study using positron emission tomography. British Journal of Haematology, 1999, 104, 296-302.	2.5	71
41	Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 2245-2255.	6.4	69
42	Imaging of Human Epidermal Growth Factor Receptor Type 2 Expression with 18F-Labeled Affibody Molecule ZHER2:2395 in a Mouse Model for Ovarian Cancer. Journal of Nuclear Medicine, 2012, 53, 146-153.	5.0	66
43	Specific Uptake of an Amyloid-Î² Protofibril-Binding Antibody-Tracer in AÎ²PP Transgenic Mouse Brain. Journal of Alzheimer's Disease, 2013, 37, 29-40.	2.6	65
44	Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors. Journal of Nuclear Medicine, 2006, 47, 512-9.	5.0	65
45	Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 631-638.	6.4	64
46	Liver uptake of radiolabeled targeting proteins and peptides: considerations for targeting peptide conjugate design. Drug Discovery Today, 2012, 17, 1224-1232.	6.4	64
47	Influence of Labelling Methods on Biodistribution and Imaging Properties of Radiolabelled Peptides for Visualisation of Molecular Therapeutic Targets. Current Medicinal Chemistry, 2010, 17, 2636-2655.	2.4	63
48	Synthesis and Characterization of a High-Affinity NOTA-Conjugated Bombesin Antagonist for GRPR-Targeted Tumor Imaging. Bioconjugate Chemistry, 2013, 24, 1144-1153.	3.6	62
49	[177Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 1457-1462.	6.4	61
50	Inhibiting HER3-Mediated Tumor Cell Growth with Affibody Molecules Engineered to Low Picomolar Affinity by Position-Directed Error-Prone PCR-Like Diversification. PLoS ONE, 2013, 8, e62791.	2.5	61
51	Pharmacokinetics and red cell utilization of 52 Fe/59 Fe-labelled iron polymaltose in anaemic patients using positron emission tomography. British Journal of Haematology, 2003, 120, 853-859.	2.5	59
52	Update: Affibody Molecules for Molecular Imaging and Therapy for Cancer. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22, 573-584.	1.0	58
53	Elimination of Stabilised Hyaluronan from the Knee Joint in Healthy Men. Clinical Pharmacokinetics, 2002, 41, 603-613.	3.5	57
54	Affibody-mediated PET imaging of HER3 expression in malignant tumours. Scientific Reports, 2015, 5, 15226.	3.3	56

#	Article	IF	Citations
55	Affibody Molecules as Targeting Vectors for PET Imaging. Cancers, 2020, 12, 651.	3.7	56
56	Binding of tellurium to hepatocellular selenoproteins during incubation with inorganic tellurite: consequences for the activity of selenium-dependent glutathione peroxidase. International Journal of Biochemistry and Cell Biology, 1999, 31, 291-301.	2.8	55
57	The Effect of Mini-PEG-Based Spacer Length on Binding and Pharmacokinetic Properties of a 68Ga-Labeled NOTA-Conjugated Antagonistic Analog of Bombesin. Molecules, 2014, 19, 10455-10472.	3.8	55
58	ADAPT, a Novel Scaffold Protein-Based Probe for Radionuclide Imaging of Molecular Targets That Are Expressed in Disseminated Cancers. Cancer Research, 2015, 75, 4364-4371.	0.9	55
59	Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy. Current Opinion in Drug Discovery & Development, 2007, 10, 167-75.	1.9	55
60	Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 692-701.	6.4	54
61	HAHAHA, HEHEHE, HIHIHI, or HKHKHK: Influence of Position and Composition of Histidine Containing Tags on Biodistribution of [^{99m}Tc(CO)₃]⁺-Labeled Affibody Molecules. Journal of Medicinal Chemistry, 2013, 56, 4966-4974.	6.4	54
62	In Vivo Evaluation of Cysteine-Based Chelators for Attachment of ^{99m}Tc to Tumor-Targeting Affibody Molecules. Bioconjugate Chemistry, 2007, 18, 549-558.	3.6	53
63	Use of a HEHEHE Purification Tag Instead of a Hexahistidine Tag Improves Biodistribution of Affibody Molecules Site-Specifically Labeled with ^{99m}Tc, ¹¹¹In, and ¹²⁵I. Journal of Medicinal Chemistry, 2011, 54, 3817-3826.	6.4	53
64	Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors. Theranostics, 2016, 6, 93-103.	10.0	53
65	[177Lu]Pertuzumab: Experimental Therapy of HER-2â€“Expressing Xenografts. Cancer Research, 2007, 67, 326-331.	0.9	52
66	Radionuclide Molecular Imaging Using Affibody Molecules. Current Pharmaceutical Biotechnology, 2010, 11, 581-589.	1.6	52
67	Radiobromination of anti-HER2/neu/ErbB-2 monoclonal antibody using the p-isothiocyanatobenzene derivative of the [76Br]undecahydro-bromo-7,8-dicarba-nido-undecaborate(1-) ion. Nuclear Medicine and Biology, 2004, 31, 425-433.	0.6	51
68	Influence of Macrocyclic Chelators on the Targeting Properties of 68Ga-Labeled Synthetic Affibody Molecules: Comparison with 111In-Labeled Counterparts. PLoS ONE, 2013, 8, e70028.	2.5	50
69	Imaging of Platelet-Derived Growth Factor Receptor Î² Expression in Glioblastoma Xenografts Using Affibody Molecule ¹¹¹In-DOTA-Z09591. Journal of Nuclear Medicine, 2014, 55, 294-300.	5.0	50
70	PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR:2377 affibody molecules. International Journal of Oncology, 2016, 48, 1325-1332.	3.3	50
71	Evaluation of ((4-Hydroxyphenyl)ethyl)maleimide for Site-Specific Radiobromination of Anti-HER2 Affibody. Bioconjugate Chemistry, 2005, 16, 1547-1555.	3.6	49
72	Radionuclide Therapy of HER2-Expressing Human Xenografts Using Affibody-Based Peptide Nucleic Acidâ€“Mediated Pretargeting: In Vivo Proof of Principle. Journal of Nuclear Medicine, 2018, 59, 1092-1098.	5.0	48

#	Article	IF	Citations
73	Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 531-539.	6.4	46
74	The effect of macrocyclic chelators on the targeting properties of the 68 Ga-labeled gastrin releasing peptide receptor antagonist PEG 2 -RM26. Nuclear Medicine and Biology, 2015, 42, 446-454.	0.6	46
75	Feasibility of Affibody-Based Bioorthogonal Chemistryâ€“Mediated Radionuclide Pretargeting. Journal of Nuclear Medicine, 2016, 57, 431-436.	5.0	46
76	Gallium-68-Labeled Affibody Molecule for PET Imaging of PDGFRÎ² Expression in Vivo. Molecular Pharmaceutics, 2014, 11, 3957-3964.	4.6	45
77	Polyhedral Boron Compounds as Potential Linkers for Attachment of Radiohalogens to Targeting Proteins and Peptides. A Review. Collection of Czechoslovak Chemical Communications, 2002, 67, 913-935.	1.0	44
78	Effects of Lysine-Containing Mercaptoacetyl-Based Chelators on the Biodistribution of ^{99m}Tc-Labeled Anti-HER2 Affibody Molecules. Bioconjugate Chemistry, 2008, 19, 2568-2576.	3.6	44
79	Imaging of Insulinlike Growth Factor Type 1 Receptor in Prostate Cancer Xenografts Using the Affibody Molecule ¹¹¹In-DOTA-Z_{IGF1R:4551}. Journal of Nuclear Medicine, 2012, 53, 90-97.	5.0	44
80	In Vitro and In Vivo Evaluation of a 18F-Labeled High Affinity NOTA Conjugated Bombesin Antagonist as a PET Ligand for GRPR-Targeted Tumor Imaging. PLoS ONE, 2013, 8, e81932.	2.5	44
81	Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1864-1873.	6.4	43
82	Influence of Nuclides and Chelators on Imaging Using Affibody Molecules: Comparative Evaluation of Recombinant Affibody Molecules Site-Specifically Labeled with ⁶⁸Ga and ¹¹¹In via Maleimido Derivatives of DOTA and NODAGA. Bioconjugate Chemistry, 2013, 24, 1102-1109.	3.6	43
83	Radiobromination of closo-dodecaborate anion. Aspects of labelling chemistry in aqueous solution using Chloramine-T. Radiochimica Acta, 2002, 90, 229-235.	1.2	41
84	186Re-maSGS-ZHER2:342, a potential Affibody conjugate for systemic therapy of HER2-expressing tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 260-269.	6.4	41
85	Phase I Study of ^{99m}Tc-ADAPT6, a Scaffold Proteinâ€“Based Probe for Visualization of HER2 Expression in Breast Cancer. Journal of Nuclear Medicine, 2021, 62, 493-499.	5.0	41
86	Targeting peptides and positron emission tomography. Biopolymers, 2002, 66, 381-392.	2.4	40
87	Approaches to Improve Cellular Retention of Radiohalogen Labels Delivered by Internalising Tumour-Targeting Proteins and Peptides. Current Medicinal Chemistry, 2003, 10, 2447-2460.	2.4	40
88	Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 481-492.	6.4	40
89	Methods for Radiolabelling of Monoclonal Antibodies. Methods in Molecular Biology, 2014, 1060, 309-330.	0.9	40
90	Imaging of HER3-expressing xenografts in mice using a 99mTc(CO)3-HEHEHE-ZHER3:08699 affibody molecule. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1450-1459.	6.4	40

#	Article	IF	Citations
91	Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors. Journal of Controlled Release, 2018, 288, 84-95.	9.9	40
92	Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1337-1346.	6.4	39
93	Radiobromination of monoclonal antibody using potassium [76Br] (4) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 667 Td (isothioc Medicine and Biology, 2004, 31, 205-211.	0.6	38
94	[99mTc(CO)3]+-(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 439-449.	6.4	38
95	Influence of Histidine-Containing Tags on the Biodistribution of ADAPT Scaffold Proteins. Bioconjugate Chemistry, 2016, 27, 716-726.	3.6	38
96	Imaging using radiolabelled targeted proteins: radioimmunodetection and beyond. EJNMMI Radiopharmacy and Chemistry, 2020, 5, 16.	3.9	38
97	Cellular processing of 125I- and 111in-labeled epidermal growth factor (EGF) bound to cultured A431 tumor cells. Nuclear Medicine and Biology, 2000, 27, 827-835.	0.6	36
98	110mIn-DTPA-D-Phe1-octreotide for imaging of neuroendocrine tumors with PET. Journal of Nuclear Medicine, 2002, 43, 1391-7.	5.0	36
99	Evaluation of a Maleimido Derivative of CHX-Aâ€²â€² DTPA for Site-Specific Labeling of Affibody Molecules. Bioconjugate Chemistry, 2008, 19, 1579-1587.	3.6	35
100	Novel chemoselective ¹⁸F-radiolabeling of thiol-containing biomolecules under mild aqueous conditions. Chemical Communications, 2016, 52, 6083-6086.	4.1	35
101	Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties. Molecular Pharmaceutics, 2019, 16, 995-1008.	4.6	35
102	Closo-Dodecaborate(2-) as a Linker for Iodination of Macromolecules. Aspects on Conjugation Chemistry and Biodistribution. Bioconjugate Chemistry, 1999, 10, 338-345.	3.6	34
103	Influence of DOTA Chelator Position on Biodistribution and Targeting Properties of ¹¹¹In-Labeled Synthetic Anti-HER2 Affibody Molecules. Bioconjugate Chemistry, 2012, 23, 1661-1670.	3.6	34
104	Optimal composition and position of histidine-containing tags improves biodistribution of 99mTc-labeled DARPin G3. Scientific Reports, 2019, 9, 9405.	3.3	34
105	Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules. Molecular Pharmaceutics, 2016, 13, 1668-1678.	4.6	33
106	Affinity recovery of eight HER2-binding affibody variants using an anti-idiotypic affibody molecule as capture ligand. Protein Expression and Purification, 2011, 76, 127-135.	1.3	32
107	Imaging of CAIX-expressing xenografts in vivo using 99mTc-HEHEHE-ZCAIX:1 Affibody molecule. International Journal of Oncology, 2015, 46, 513-520.	3.3	31
108	Design, Preparation, and Characterization of PNA-Based Hybridization Probes for Affibody-Molecule-Mediated Pretargeting. Bioconjugate Chemistry, 2015, 26, 1724-1736.	3.6	31

#	Article	IF	Citations
109	Cyclic versus Noncyclic Chelating Scaffold for ⁸⁹Zr-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression. Molecular Pharmaceutics, 2018, 15, 175-185.	4.6	31
110	High yield [125I]iodide-labeling of iodinated carboranes by palladium-catalyzed isotopic exchange. Journal of Organometallic Chemistry, 2003, 680, 188-192.	1.8	30
111	A limiting factor for the progress of radionuclide-based cancer diagnostics and therapy Availability of suitable radionuclides. Acta OncolÃ³gica, 2004, 43, 264-275.	1.8	30
112	Comparative evaluation of 111In-labeled NOTA-conjugated affibody molecules for visualization of HER3 expression in malignant tumors. Oncology Reports, 2015, 34, 1042-1048.	2.6	30
113	Comparative Evaluation of Affibody Molecules for Radionuclide Imaging of in Vivo Expression of Carbonic Anhydrase IX. Molecular Pharmaceutics, 2016, 13, 3676-3687.	4.6	30
114	Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors. Contrast Media and Molecular Imaging, 2018, 2018, 1-11.	0.8	30
115	Trastuzumab cotreatment improves survival of mice with PCâ€3 prostate cancer xenografts treated with the GRPR antagonist ¹⁷⁷Luâ€DOTAGAâ€PEG₂â€RM26. International Journal of Cancer, 2019, 145, 3347-3358.	5.1	30
116	High yield direct 76Br-bromination of monoclonal antibodies using chloramine-T. Nuclear Medicine and Biology, 1999, 26, 923-929.	0.6	29
117	Kit formulation for 99mTc-labeling of recombinant anti-HER2 Affibody molecules with a C-terminally engineered cysteine. Nuclear Medicine and Biology, 2010, 37, 539-546.	0.6	29
118	Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26. International Journal of Oncology, 2016, 48, 2124-2134.	3.3	29
119	The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated Affibody molecule. Scientific Reports, 2017, 7, 5961.	3.3	29
120	Radionuclide Tumor Targeting Using ADAPT Scaffold Proteins: Aspects of Label Positioning and Residualizing Properties of the Label. Journal of Nuclear Medicine, 2018, 59, 93-99.	5.0	29
121	Phase I Trial of ^{99m}Tc-(HE)₃-G3, a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer. Journal of Nuclear Medicine, 2022, 63, 528-535.	5.0	29
122	114mIn, a candidate for radionuclide therapy: low-energy cyclotron production and labeling of DTPA-D-Phe-octreotide. Nuclear Medicine and Biology, 2000, 27, 183-188.	0.6	28
123	Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In- and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 Affibody. Nuclear Medicine and Biology, 2011, 38, 1093-1102.	0.6	28
124	The influence of Bz-DOTA and CHX-Aâ€³-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for 114mIn-mediated targeting therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1460-1468.	6.4	27
125	Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with 99mTc using a peptide-based cysteine-containing chelator. International Journal of Oncology, 2016, 49, 2285-2293.	3.3	27
126	High Contrast PET Imaging of GRPR Expression in Prostate Cancer Using Cobalt-Labeled Bombesin Antagonist RM26. Contrast Media and Molecular Imaging, 2017, 2017, 1-10.	0.8	27

#	Article	IF	Citations
127	The emerging role of radionuclide molecular imaging of HER2 expression in breast cancer. Seminars in Cancer Biology, 2021, 72, 185-197.	9.6	27
128	Kinetic analysis of 52 Fe-labelled iron(III) hydroxide-sucrose complex following bolus administration using positron emission tomography. British Journal of Haematology, 1999, 104, 288-295.	2.5	26
129	Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211 At-EGF. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 1348-1356.	6.4	26
130	Evaluation of the first 44Sc-labeled Affibody molecule for imaging of HER2-expressing tumors. Nuclear Medicine and Biology, 2017, 45, 15-21.	0.6	26
131	Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer. Cancers, 2019, 11, 1371.	3.7	26
132	Labelling chemistry and characterization of [90Y/177Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma. International Journal of Molecular Medicine, 2007, 19, 285-91.	4.0	26
133	Rapid separation of gallium from zinc targets by thermal diffusion. Applied Radiation and Isotopes, 1996, 47, 297-299.	1.5	25
134	Evaluation of a Maleimido Derivative of NOTA for Site-Specific Labeling of Affibody Molecules. Bioconjugate Chemistry, 2011, 22, 894-902.	3.6	25
135	Incorporation of a Triglutamyl Spacer Improves the Biodistribution of Synthetic Affibody Molecules Radiofluorinated at the N-Terminus via Oxime Formation with ¹⁸F-4-Fluorobenzaldehyde. Bioconjugate Chemistry, 2014, 25, 82-92.	3.6	25
136	Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model. Theranostics, 2018, 8, 4462-4476.	10.0	25
137	Biodistribution of 211At labeled HER-2 binding affibody molecules in mice. Oncology Reports, 2007, 17, 1141-7.	2.6	25
138	Radiobromination of humanized anti-HER2 monoclonal antibody trastuzumab using N-succinimidyl 5-bromo-3-pyridinecarboxylate, a potential label for immunoPET. Nuclear Medicine and Biology, 2005, 32, 613-622.	0.6	24
139	Influence of molecular design on biodistribution and targeting properties of an Affibody-fused HER2-recognising anticancer toxin. International Journal of Oncology, 2016, 49, 1185-1194.	3.3	24
140	In vitro evaluation of the astatinated chimeric monoclonal antibody U36, a potential candidate for treatment of head and neck squamous cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 1296-1304.	6.4	23
141	¹⁸⁸Re-Z_{HER2:V2}, a Promising Affibody-Based Targeting Agent Against HER2-Expressing Tumors: Preclinical Assessment. Journal of Nuclear Medicine, 2014, 55, 1842-1848.	5.0	23
142	Positron Emission Tomography and Radioimmunotargeting: General Aspects. Acta OncolÃ³gica, 1999, 38, 335-341.	1.8	22
143	Optimized indirect 76br-bromination of antibodies using n-succinimidyl para-[76br]bromobenzoate for radioimmuno PET. Nuclear Medicine and Biology, 2000, 27, 837-843.	0.6	22
144	Title is missing!. Journal of Radioanalytical and Nuclear Chemistry, 2003, 256, 191-197.	1.5	22

#	Article	IF	Citations
145	Imaging agents for in vivo molecular profiling of disseminated prostate cancer: Cellular processing of [111In]-labeled CHX-Aâ€³DTPA-trastuzumab and anti-HER2 ABY-025 Affibody in prostate cancer cell lines. Experimental and Therapeutic Medicine, 2011, 2, 523-528.	1.8	22
146	Evaluation of 99mTc-ZIGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression. Amino Acids, 2015, 47, 303-315.	2.7	22
147	Evaluation of HER2-specific peptide ligand for its employment as radiolabeled imaging probe. Scientific Reports, 2018, 8, 2998.	3.3	22
148	CAIX-targeting radiotracers for hypoxia imaging in head and neck cancer models. Scientific Reports, 2019, 9, 18898.	3.3	22
149	Synthesis and radioiodination of some daunorubicin and doxorubicin derivatives. Carbohydrate Research, 2005, 340, 15-24.	2.3	21
150	In vitro and in vivo characterization of 177Lu-huA33. Nuclear Medicine and Biology, 2006, 33, 991-998.	0.6	21
151	Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus. Tumor Biology, 2012, 33, 641-651.	1.8	21
152	Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin ZHER2:2891-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domain. International Journal of Oncology, 2015, 47, 601-609.	3.3	21
153	Enhanced protection of the renal vascular endothelium improves early outcome in kidney transplantation: Preclinical investigations in pig and mouse. Scientific Reports, 2018, 8, 5220.	3.3	21
154	Preclinical Evaluation of [68Ga]Ga-DFO-ZEGFR:2377: A Promising Affibody-Based Probe for Noninvasive PET Imaging of EGFR Expression in Tumors. Cells, 2018, 7, 141.	4.1	21
155	Selection of the optimal macrocyclic chelators for labeling with 111In and 68Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 140, 109-120.	4.3	21
156	Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of 68Ga-Labeled Tracers. International Journal of Molecular Sciences, 2019, 20, 1080.	4.1	21
157	Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumours. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 134, 37-48.	4.3	21
158	Pre-clinical evaluation of [111In]-benzyl-DOTA-Z(HER2:342), a potential agent for imaging of HER2 expression in malignant tumors. International Journal of Molecular Medicine, 2007, 20, 397-404.	4.0	21
159	Conjugate Chemistry and Cellular Processing of EGF-Dextran. Acta OncolÃ³gica, 1999, 38, 313-321.	1.8	20
160	Production, PET performance and dosimetric considerations of134Ce/134La, an Auger electron and positron-emitting generator for radionuclide therapy. Physics in Medicine and Biology, 2002, 47, 615-629.	3.0	20
161	Protein interactions with HER-family receptors can have different characteristics depending on the hosting cell line. International Journal of Oncology, 2011, 40, 1677-82.	3.3	20
162	In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct. Scientific Reports, 2017, 7, 43118.	3.3	20

#	Article	IF	Citations
163	Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1. International Journal of Biological Macromolecules, 2020, 145, 216-225.	7.5	20
164	Synthesis of N-Succinimidyl 4-[76Br]Bromobenzoate and its Use in Conjugation Labelling of Macromolecules.. Acta Chemica Scandinavica, 1999, 53, 508-512.	0.7	20
165	Production of 61Cu from a natural nickel target. Applied Radiation and Isotopes, 1998, 49, 79-81.	1.5	19
166	Biodistribution of the Chimeric Monoclonal Antibody U36 Radioiodinated with a closo-Dodecaborate-Containing Linker. Comparison with Other Radioiodination Methods. Bioconjugate Chemistry, 2003, 14, 805-810.	3.6	19
167	Planning for Intracavitary Anti-EGFR Radionuclide Therapy of Gliomas. Literature Review and Data on EGFR Expression. Journal of Neuro-Oncology, 2006, 77, 33-45.	2.9	19
168	Differences in radiosensitivity between three HER2 overexpressing cell lines. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1179-1191.	6.4	19
169	Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with 188Re. European Journal of Medicinal Chemistry, 2014, 87, 519-528.	5.5	19
170	Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs. Cells, 2018, 7, 164.	4.1	19
171	Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab. Molecular Pharmaceutics, 2018, 15, 3394-3403.	4.6	19
172	Site-specific conjugation of recognition tags to trastuzumab for peptide nucleic acid-mediated radionuclide HER2 pretargeting. Biomaterials, 2019, 203, 73-85.	11.4	19
173	Comparison of tumorâ€'targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2. International Journal of Oncology, 2019, 54, 1209-1220.	3.3	19
174	Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancerâ€"Optimization of the Affinity towards PSMA by Linker Modification in Murine Model. Pharmaceutics, 2020, 12, 614.	4.5	19
175	Targeted nuclear medicine. Seek and destroy. Russian Chemical Reviews, 2022, 91, .	6.5	19
176	Closo-dodecaborate (2-) anion as a potential prosthetic group for attachment of astatine to proteins. Aspects of the labelling chemistry with chloramine-T. Journal of Labelled Compounds and Radiopharmaceuticals, 2000, 43, 251-260.	1.0	18
177	Optimization of HER3 expression imaging using affibody molecules: Influence of chelator for labeling with indium-111. Scientific Reports, 2019, 9, 655.	3.3	18
178	Indirect Radioiodination of DARPin G3 Using N-succinimidyl-Para-Iodobenzoate Improves the Contrast of HER2 Molecular Imaging. International Journal of Molecular Sciences, 2019, 20, 3047.	4.1	18
179	PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology. International Journal of Molecular Sciences, 2021, 22, 3663.	4.1	18
180	Positioning of 99mTc-chelators influences radiolabeling, stability and biodistribution of Affibody molecules. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 3912-3914.	2.2	17

#	Article	IF	Citations
181	Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m. Scientific Reports, 2017, 7, 14780.	3.3	17
182	Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer. Pharmaceutics, 2019, 11, 358.	4.5	17
183	Feasibility of Imaging EpCAM Expression in Ovarian Cancer Using Radiolabeled DARPin Ec1. International Journal of Molecular Sciences, 2020, 21, 3310.	4.1	17
184	Histidine-Rich Glycoprotein Uptake and Turnover Is Mediated by Mononuclear Phagocytes. PLoS ONE, 2014, 9, e107483.	2.5	17
185	A method of drug delivery to tumors based on rapidly biodegradable drug-loaded containers. Applied Materials Today, 2021, 25, 101199.	4.3	17
186	Rapid separation of 110In from enriched Cd targets by thermal diffusion. Applied Radiation and Isotopes, 1995, 46, 859-863.	1.5	16
187	Positron Emission Tomography and Radioimmunotargeting: Aspects of Quantification and Dosimetry. Acta OncolÃ³gica, 1999, 38, 343-349.	1.8	16
188	Effects of Dextranation on the Pharmacokinetics of Short Peptides. A PET Study on mEGF. Bioconjugate Chemistry, 1999, 10, 938-946.	3.6	16
189	Separation of arsenic from germanium oxide targets by dry distillation. Journal of Radioanalytical and Nuclear Chemistry, 2001, 247, 61-66.	1.5	16
190	[111In]Bz-DTPA-hEGF: Preparation andIn VitroCharacterization of a Potential Anti-Glioblastoma Targeting Agent. Cancer Biotherapy and Radiopharmaceuticals, 2003, 18, 643-654.	1.0	16
191	Effect of cetuximab in combination with alpha-radioimmunotherapy in cultured squamous cell carcinomas. Nuclear Medicine and Biology, 2011, 38, 103-112.	0.6	16
192	Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of 99mTc-labeled recombinant Affibody molecules. Amino Acids, 2012, 42, 1975-1985.	2.7	16
193	Influence of composition of cysteine-containing peptide-based chelators on biodistribution of 99mTc-labeled anti-EGFR affibody molecules. Amino Acids, 2018, 50, 981-994.	2.7	16
194	Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model. Cancers, 2021, 13, 85.	3.7	16
195	Kinetics of 76Br-labeled anti-CEA antibodies in pigs; Aspects of dosimetry and PET imaging properties. Medical Physics, 1999, 26, 249-258.	3.0	15
196	Quantification of CD44v6 and EGFR Expression in Head and Neck Squamous Cell Carcinomas Using a Single-Dose Radioimmunoassay. Tumor Biology, 2007, 28, 253-263.	1.8	15
197	Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with 111In using a maleimido derivative of NODAGA. Nuclear Medicine and Biology, 2012, 39, 518-529.	0.6	15
198	Evaluation of backbone-cyclized HER2-binding 2-helix Affibody molecule for In Vivo molecular imaging. Nuclear Medicine and Biology, 2013, 40, 378-386.	0.6	15

#	Article	IF	Citations
199	Optimized Molecular Design of ADAPT-Based HER2-Imaging Probes Labeled with ¹¹¹In and ⁶⁸Ga. Molecular Pharmaceutics, 2018, 15, 2674-2683.	4.6	15
200	Comparative Biodistribution of the Radiohalogenated (Br, I and At) Antibody A33. Implications for In Vivo Dosimetry.. Cancer Biotherapy and Radiopharmaceuticals, 2002, 17, 385-396.	1.0	14
201	Treatment of cultured glioma cells with the EGFR-TKI gefitinib ("Iressa", ZD1839) increases the uptake of astatinated EGF despite the absence of gefitinib-mediated growth inhibition. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 727-729.	6.4	14
202	Labelling chemistry and characterization of [90Y/177Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma. International Journal of Molecular Medicine, 2007, 19, 285.	4.0	14
203	Radioimmunotherapy With Astatine-211 Using Chimeric Monoclonal Antibody U36 in Head and Neck Squamous Cell Carcinoma. Laryngoscope, 2007, 117, 1013-1018.	2.0	14
204	Synthesis and chemoselective intramolecular crosslinking of a HER2â€binding affibody. Biopolymers, 2009, 92, 116-123.	2.4	14
205	Development of a 124I-labeled version of the anti-PSMA monoclonal antibody capromab for immunoPET staging of prostate cancer: Aspects of labeling chemistry and biodistribution. International Journal of Oncology, 2014, 44, 1998-2008.	3.3	14
206	Comparative Evaluation of Anti-HER2 Affibody Molecules Labeled with ⁶⁴Cu Using NOTA and NODAGA. Contrast Media and Molecular Imaging, 2017, 2017, 1-12.	0.8	14
207	Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26. Scientific Reports, 2019, 9, 17086.	3.3	14
208	Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts. Scientific Reports, 2019, 9, 14907.	3.3	14
209	Increase in negative charge of 68Ga/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules. Scientific Reports, 2019, 9, 17710.	3.3	14
210	Preclinical Evaluation of 99mTc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake. International Journal of Molecular Sciences, 2021, 22, 2770.	4.1	14
211	Radiolabeled Probes Targeting Tyrosine-Kinase Receptors For Personalized Medicine. Current Pharmaceutical Design, 2014, 20, 2275-2292.	1.9	14
212	Synthesis and radioiodination of 7-(3â€²-ammoniopropyl)-7,8-dicarba-nido-undecaborate(-1),(ANC). Journal of Labelled Compounds and Radiopharmaceuticals, 2004, 47, 557-569.	1.0	13
213	Biodistribution of 211At labeled HER-2 binding affibody molecules in mice. Oncology Reports, 2007, , .	2.6	13
214	Imaging agents for in vivo molecular profiling of disseminated prostate cancer - targeting EGFR receptors in prostate cancer: Comparison of cellular processing of [111In]-labeled affibody molecule ZEGFR:2377 and cetuximab. International Journal of Oncology, 2011, 38, 1137-43.	3.3	13
215	Evaluation of a novel type of imaging probe based on a recombinant bivalent mini-antibody construct for detection of CD44v6-expressing squamous cell carcinoma. International Journal of Oncology, 2016, 48, 461-470.	3.3	13
216	Influence of the N-Terminal Composition on Targeting Properties of Radiometal-Labeled Anti-HER2 Scaffold Protein ADAPT6. Bioconjugate Chemistry, 2016, 27, 2678-2688.	3.6	13

#	Article	IF	Citations
217	Molecular design of radiocopper-labelled Affibody molecules. Scientific Reports, 2018, 8, 6542.	3.3	13
218	Comparative Biodistribution of Potential Anti-Glioblastoma Conjugates [¹¹¹In]DTPA-hEGF and [¹¹¹In]Bz-DTPA-hEGF in Normal Mice. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19, 491-501.	1.0	13
219	[177Lu]Bz-DTPA-EGF: Preclinical Characterization of a Potential Radionuclide Targeting Agent Against Glioma. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19, 195-204.	1.0	12
220	Comparative Biodistribution of Potential Anti- Glioblastoma Conjugates [111In]DTPA-hEGF and [111In]Bz-DTPA-hEGF in Normal Mice. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19, 491-502.	1.0	12
221	Radiobromination ofcloso-carboranes using palladium-catalyzed halogen exchange. Journal of Labelled Compounds and Radiopharmaceuticals, 2005, 48, 195-202.	1.0	12
222	Biodistribution of211At-Labeled Humanized Monoclonal Antibody A33. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22, 480-487.	1.0	12
223	Targeting Free Prostate-Specific Antigen forIn VivoImaging of Prostate Cancer Using a Monoclonal Antibody Specific for Unique Epitopes Accessible on Free Prostate-Specific Antigen Alone. Cancer Biotherapy and Radiopharmaceuticals, 2012, 27, 243-251.	1.0	12
224	Position for Site-Specific Attachment of a DOTA Chelator to Synthetic Affibody Molecules Has a Different Influence on the Targeting Properties of ⁶⁸ Ga-Compared to ¹¹¹ In-Labeled Conjugates. Molecular Imaging, 2014, 13, 7290.2014.00034.	1.4	12
225	Siteâ€Specific Radioiodination of HER2â€Targeting Affibody Molecules using 4â€Iodophenethylmaleimide Decreases Renal Uptake of Radioactivity. ChemistryOpen, 2015, 4, 174-182.	1.9	12
226	Control of growth factor binding and release in bisphosphonate functionalized hydrogels guides rapid differentiation of precursor cells in vitro. Biomaterials Science, 2016, 4, 250-254.	5.4	12
227	Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibodyâ€“DM1 Drug Conjugates. Cancers, 2019, 11, 1168.	3.7	12
228	Evaluation of an antibody-PNA conjugate as a clearing agent for antibody-based PNA-mediated radionuclide pretargeting. Scientific Reports, 2020, 10, 20777.	3.3	12
229	Comparative Evaluation of Novel 177Lu-Labeled PNA Probes for Affibody-Mediated PNA-Based Pretargeting. Cancers, 2021, 13, 500.	3.7	12
230	Radiobromine-Labelled Tracers for Positron Emission Tomography: Possibilities and Pitfalls. Current Radiopharmaceuticals, 2011, 4, 76-89.	0.8	12
231	Quantification aspects of patient studies with 52Fe in positron emission tomography. Applied Radiation and Isotopes, 1999, 51, 707-715.	1.5	11
232	Feasibility of palladium-catalyzed isotopic exchange between sodium [125I]I and 2-iodo-para-carborane. Journal of Labelled Compounds and Radiopharmaceuticals, 2003, 46, 623-631.	1.0	11
233	In Vitro Characterization of 211At-Labeled Antibody A33â€”a Potential Therapeutic Agent Against Metastatic Colorectal Carcinoma. Cancer Biotherapy and Radiopharmaceuticals, 2005, 20, 514-523.	1.0	11
234	Direct comparison of 111In-labelled two-helix and three-helix Affibody molecules for in vivo molecular imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 693-702.	6.4	11

#	Article	IF	Citations
235	Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy. Scientific Reports, 2018, 8, 9643.	3.3	11
236	Radionuclide Molecular Imaging of EpCAM Expression in Triple-Negative Breast Cancer Using the Scaffold Protein DARPin Ec1. Molecules, 2020, 25, 4719.	3.8	11
237	Radionuclide therapy using ABD-fused ADAPT scaffold protein: Proof of Principle. Biomaterials, 2021, 266, 120381.	11.4	11
238	Kinetic analysis of HER2-binding ABY-025 Affibody molecule using dynamic PET in patients with metastatic breast cancer. EJNMMI Research, 2020, 10, 21.	2.5	11
239	Influence of Cell Proportions and Proliferation Rates on FDG Uptake in Squamous-Cell Esophageal Carcinoma: A PET Study. Cancer Biotherapy and Radiopharmaceuticals, 2008, 23, 172-180.	1.0	10
240	Preparation and in vitro evaluation of 111In-CHX-A"-DTPA-labeled anti-VEGF monoclonal antibody bevacizumab. Human Antibodies, 2010, 19, 107-111.	1.5	10
241	Evaluation of a radiocobalt-labelled affibody molecule for imaging of human epidermal growth factor receptor 3 expression. International Journal of Oncology, 2017, 51, 1765-1774.	3.3	10
242	Potent and specific fusion toxins consisting of a HER2â€'binding, ABDâ€'derived affinity protein, fused to truncated versions of Pseudomonas exotoxinï¿½A. International Journal of Oncology, 2019, 55, 309-319.	3.3	10
243	Basic and practical concepts of radiopharmaceutical purification methods. Drug Discovery Today, 2019, 24, 315-324.	6.4	10
244	66Ga-PET-imaging of GRPR-expression in prostate cancer: production and characterization of [66Ga]Ga-NOTA-PEG2-RM26. Scientific Reports, 2021, 11, 3631.	3.3	10
245	The Use of a Non-Conventional Long-Lived Gallium Radioisotope 66Ga Improves Imaging Contrast of EGFR Expression in Malignant Tumours Using DFO-ZEGFR:2377 Affibody Molecule. Pharmaceutics, 2021, 13, 292.	4.5	10
246	[99mTc] HYNIC-hEGF, a potential agent for imaging of EGF receptors in vivo: preparation and pre-clinical evaluation. Oncology Reports, 2005, 13, 1169-75.	2.6	10
247	Radio-iodination of monoclonal antibody using potassium [125I]-(4-isothiocyanatobenzylammonio)-iodo-decahydro-closo-dodecaborate (iodo-DABI). Anticancer Research, 2006, 26, 1217-23.	1.1	10
248	Performance of coincidence imaging with long-lived positron emitters as an alternative to dedicated PET and SPECT. Physics in Medicine and Biology, 2004, 49, 5419-5432.	3.0	9
249	Preparation, radioiodination and in vitro evaluation of a nido-carborane-dextran conjugate, a potential residualizing label for tumor targeting proteins and peptides. Journal of Radioanalytical and Nuclear Chemistry, 2004, 261, 107-112.	1.5	9
250	Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model. Pharmaceutics, 2020, 12, 551.	4.5	9
251	Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules. International Journal of Molecular Sciences, 2020, 21, 1972.	4.1	9
252	Radiolabeled GRPR Antagonists for Imaging of Disseminated Prostate Cancer - Influence of Labeling Chemistry on Targeting Properties. Current Medicinal Chemistry, 2020, 27, 7090-7111.	2.4	9

#	Article	IF	Citations
253	Affibody-Mediated PNA-Based Pretargeted Cotreatment Improves Survival of Trastuzumab-Treated Mice Bearing HER2-Expressing Xenografts. Journal of Nuclear Medicine, 2022, 63, 1046-1051.	5.0	9
254	Synthesis and radioiodination of some 9-aminoacridine derivatives for potential use in radionuclide therapy. Journal of Labelled Compounds and Radiopharmaceuticals, 2005, 48, 855-871.	1.0	8
255	Influence of an aliphatic linker between DOTA and synthetic ZHER2:342 Affibody molecule on targeting properties of the 111In-labeled conjugate. Nuclear Medicine and Biology, 2011, 38, 697-706.	0.6	8
256	Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake. Scientific Reports, 2019, 9, 6779.	3.3	8
257	Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer. Pharmaceutics, 2020, 12, 977.	4.5	8
258	Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution. Pharmaceutics, 2021, 13, 430.	4.5	8
259	Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model. Cancers, 2021, 13, 3939.	3.7	8
260	Choice of Radionuclides and Radiolabelling Techniques. , 2008, , 145-174.		8
261	Targeting against epidermal growth factor receptors. Cellular processing of astatinated EGF after binding to cultured carcinoma cells. Anticancer Research, 2004, 24, 4035-41.	1.1	8
262	Comparison of benzoate- and dodecaborate-based linkers for attachment of radioiodine to HER2-targeting Affibody ligand. International Journal of Molecular Medicine, 2007, 19, 485-93.	4.0	8
263	Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules. International Journal of Molecular Sciences, 2020, 21, 1312.	4.1	7
264	HER2-Specific Pseudomonas Exotoxin A PE25 Based Fusions: Influence of Targeting Domain on Target Binding, Toxicity, and In Vivo Biodistribution. Pharmaceutics, 2020, 12, 391.	4.5	7
265	Preclinical Evaluation of 99mTc-Labeled GRPR Antagonists maSSS/SES-PEG2-RM26 for Imaging of Prostate Cancer. Pharmaceutics, 2021, 13, 182.	4.5	7
266	Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPin Ec1. Cancers, 2021, 13, 3589.	3.7	7
267	Targeting of a Head and Neck Squamous Cell Carcinoma Xenograft Model Using the Chimeric Monoclonal Antibody U36 Radioiodinated with a closo-Dodecaborate-containing Linker. Acta Oto-Laryngologica, 2004, 124, 1078-1085.	0.9	6
268	Improved Tumor-to-Organ Ratios of a Novel ⁶⁷Ga-Human Epidermal Growth Factor Radionuclide Conjugate with Preadministered Antiepidermal Growth Factor Receptor Affibody Molecules. Cancer Biotherapy and Radiopharmaceuticals, 2011, 26, 593-601.	1.0	6
269	125I-Labeled Quercetin as a Novel DNA-Targeted Radiotracer. Cancer Biotherapy and Radiopharmaceuticals, 2011, 26, 469-475.	1.0	6
270	Evaluation of Tumor-Targeting Properties of an Antagonistic Bombesin Analogue RM26 Conjugated with a Non-Residualizing Radioiodine Label Comparison with a Radiometal-Labelled Counterpart. Pharmaceutics, 2019, 11, 380.	4.5	6

#	Article	IF	Citations
271	Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer. Molecules, 2020, 25, 5993.	3.8	6
272	Possibilities of radionuclide diagnostics of Her2-positive breast cancer using technetium-99m-labeled target molecules: the first experience of clinical use. Bulletin of Siberian Medicine, 2021, 20, 23-30.	0.3	6
273	HER3 PET Imaging: 68Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to 89Zr-Labeled Antibody and Antibody-Fragment-Based Tracers. Cancers, 2021, 13, 4791.	3.7	6
274	Comparison of benzoate- and dodecaborate-based linkers for attachment of radioiodine to HER2-targeting Affibody ligand. International Journal of Molecular Medicine, 0, , .	4.0	6
275	The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy. Pharmaceutics, 2021, 13, 1974.	4.5	6
276	Title is missing!. Journal of Radioanalytical and Nuclear Chemistry, 2000, 246, 207-213.	1.5	5
277	Title is missing!. Journal of Radioanalytical and Nuclear Chemistry, 2003, 256, 67-71.	1.5	5
278	Copper-mediated isotopic exchange between [125I]iodide and bis(triethylammonium) undecahydro-12-iodo-closo-dodecaborate in aqueous media. Journal of Radioanalytical and Nuclear Chemistry, 2004, 260, 295-299.	1.5	5
279	Synthesis and Radioiodination of Some 9-Aminoacridine Derivatives. European Journal of Organic Chemistry, 2004, 2004, 3719-3725.	2.4	5
280	Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused AffibodyÂ® Molecules 177Lu-ABY-271 and 177Lu-ABY-027: Impact of DOTA Position on ABD Domain. Pharmaceutics, 2021, 13, 839.	4.5	5
281	Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody Molecule 188Re-ZHER2:41071. Pharmaceutics, 2022, 14, 1092.	4.5	5
282	In VitroEvaluation of Two Polyhedral Boron Anion Derivatives as Linkers for Attachment of Radioiodine to the Anti-HER2 Monoclonal Antibody Trastuzumab. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22, 585-596.	1.0	4
283	Affibodyâ€'mediated imaging of EGFR expression in prostate cancer using radiocobaltâ€'labeled DOTAâ€'ZEGFR:2377. Oncology Reports, 2018, 41, 534-542.	2.6	4
284	Pre-clinical evaluation of [111In]-benzyl-DOTA-ZHER2:342, a potential agent for imaging of HER2 expression in malignant tumors. International Journal of Molecular Medicine, 0, , .	4.0	4
285	Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein. Pharmaceutics, 2021, 13, 1847.	4.5	4
286	Radionuclides in Diagnostics and Therapy of Malignant Tumors: New Development. Cancers, 2022, 14, 297.	3.7	4
287	Epithelial cell adhesion moleculeâ€'targeting designed ankyrin repeat proteinâ€'toxin fusion Ec1â€'LoPE exhibits potent cytotoxic action in prostate cancer cells. Oncology Reports, 2022, 47, .	2.6	4
288	Preclinical Evaluation of a New Format of 68Ga- and 111In-Labeled Affibody Molecule ZIGF-1R:4551 for the Visualization of IGF-1R Expression in Malignant Tumors Using PET and SPECT. Pharmaceutics, 2022, 14, 1475.	4.5	4

#	Article	IF	Citations
289	Diffusion-based separation methods: Dry distillation of zinc, cadmium and mercury isotopes from irradiated targets. Applied Radiation and Isotopes, 1997, 48, 565-569.	1.5	3
290	Positron emission tomography of experimental melanoma with [76Br]5-bromo-2-thiouracil. Nuclear Medicine and Biology, 2000, 27, 845-849.	0.6	3
291	Preparation of Conjugates for Affibody-Based PNA-Mediated Pretargeting. Methods in Molecular Biology, 2020, 2105, 283-304.	0.9	3
292	Preparation of [76Br] 5-bromo-2-thiouracil, a positron-emitting melanoma localizing agent. Journal of Radioanalytical and Nuclear Chemistry, 2002, 251, 409-412.	1.5	2
293	Radioiodination of ammonio-closo-monocarborane, 1-H3N-1-CB11H11. Aspects of labelling chemistry in aqueous solution using Chloramine-T. Radiochimica Acta, 2004, 92, 311-315.	1.2	2
294	Reply: Molecular Imaging of EGFR: It's Time to Go Beyond Receptor Expression. Journal of Nuclear Medicine, 2009, 50, 1196-1196.	5.0	2
295	[99mTc] HYNIC-hEGF, a potential agent for imaging of EGF receptors in vivo: Preparation and pre-clinical evaluation. Oncology Reports, 0, , .	2.6	2
296	Cellular processing in the SW1222 cell line of mAb A33 directly and indirectly radiohalogenated. Oncology Reports, 0, , .	2.6	2
297	Effect of Inter-Domain Linker Composition on Biodistribution of ABD-Fused Affibody-Drug Conjugates Targeting HER2. Pharmaceutics, 2022, 14, 522.	4.5	2
298	Separation of two labeled components of [111In] -OctreoScan by HPLC. Journal of Radioanalytical and Nuclear Chemistry, 2001, 247, 95-99.	1.5	1
299	Efficient Synthesis of ï‰â€{¹⁸F]Fluoroaliphatic Carboxylic Esters and Acids for Positron Emission Tomography. European Journal of Organic Chemistry, 2020, 2020, 6375-6381.	2.4	1
300	EVALUATION OF EXTENT OF BREAST CANCER IN A PATIENT WITH HER2/NEU OVEREXPRESSION USING A RADIOPHARMACEUTICAL BASED ON TECHNETIUM-99M-LABELED TARGET MOLECULES (CASE REPORT). Siberian Journal of Oncology, 2021, 20, 170-178.	0.3	1
301	Phase I Clinical Trial Using [99mTc]Tc-1-thio-D-glucose for Diagnosis of Lymphoma Patients. Pharmaceutics, 2022, 14, 1274.	4.5	1
302	Theranostic pairing: ABY-025/251 targeting HER2 with ⁶⁸Ga and ¹⁸⁸Reâ€”Minimized radioligands using Affibody peptide scaffold technology.. Journal of Clinical Oncology, 2022, 40, 3093-3093.	1.6	1
303	An aminoacridine derivative for radionuclide therapy: DNA binding properties studied in a novel cell-free in vitro assay. International Journal of Oncology, 2005, 27, 1355.	3.3	0
304	The use of closo-dodecaborate-containing linker improves targeting of HNSCC xenografts with radioiodinated chimeric monoclonal antibody U36. Molecular Medicine Reports, 2009, 3, 155-60.	2.4	0
305	Single-photon emission computerized tomography with ^{99m}TC-DARPIN9_29 in diagnostics of breast cancer with Her2/neu overexpression: first clinical experience. Molekulyarnaya Meditsina (Molecular Medicine), 2021, 19, 41-46.	0.2	0
306	Phase I clinical study of a new radiopharmaceutical based on recombinant target molecules DARPin9_29 labeled with technetium-99m for radionuclide diagnosis of the Her2/neu-positive breast cancer. Molekulyarnaya Meditsina (Molecular Medicine), 2021, 19, 41-48.	0.2	0

#	Article	IF	Citations
307	Comparative Analysis of the Clinical Use of 99mTechnetium-Labeled Recombinant Target Molecules in Different Dosages for the Radionuclide Diagnosis of Her2-Positive Breast Cancer. Vestnik Rentgenologii I Radiologii, 2021, 102, 89-97.	0.2	0
308	Non-invasive determination of HER2-expression in metastatic breast cancer by using ⁶⁸Ga-ABY025 PET/CT.. Journal of Clinical Oncology, 2015, 33, 11067-11067.	1.6	0